Markets News
Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.
Nokia Shares Plunge 21% Ahead of Q2 Report on AI Cost Pressures
Nokia shares fell 21% over six sessions, wiping out €13.5 billion in market cap, as AI-related cost warnings from Ericsson and analyst downgrades pressure the stock.
Coca-Cola Edges Up Pre-Market as Fairlife Cyber Attack Highlights $6.2B Stake
Coca-Cola shares edged higher in premarket trading after a ransomware attack disrupted fairlife production, highlighting the company's $6.2 billion investment in the dairy brand.
AtaiBeckley Merger Value Reflects 14% of CVR Face Value
AtaiBeckley shares trade at $7.091, 34 cents above Eli Lilly's cash offer, implying a CVR value of 13.6% of its maximum $2.50 face value.
Nebius shares plunge 14% as asset-light AI model raises funding concerns
Nebius Group (NBIS) shares tumbled 13.9% on Thursday after the company outlined an asset-light expansion model, raising questions about its funding strategy.
Iovance Stock Rises on Strong Amtagvi Sales Outlook
Iovance Biotherapeutics gained 10.2% as attention shifts to Amtagvi's second-half sales target of $95.8M-$105.8M per quarter.
Nu Holdings' Regional Chief Faces Valuation Hurdle as Mexico Expansion Accelerates
Nu Holdings (NU) appoints Livia Chanes as regional head, facing valuation pressure with a P/E of 21.3, as it seeks growth beyond Brazil in Mexico and Colombia.
ASX 200 Closes Lower as Materials Slide Offsets Broad Gains
The S&P/ASX 200 fell 0.50% to 8,796.7 on Friday, dragged by a 2.91% decline in materials, while seven other sectors gained. BHP, Rio Tinto, and Fortescue led the losses.
Nifty 50 Hits New High as Five Stocks Drive Two-Thirds of Gains
India's Nifty 50 advanced 1.09% to 24,334.25, driven by five major stocks that accounted for 66% of the gain, while midcap and smallcap indices declined.
Vodafone Shares Jump as Niel's Vega Boosts Voting Stake to Near 20%
Vodafone shares climbed 3.2% after Xavier Niel's Vega raised its voting stake to 19.87%, just below the 20% threshold. Vega reiterated it has no plans to make an offer, viewing the holding as a long-term strategic investment.
GSK Plummets After Failed Cough Drug Trial Wipes Out £2.36B
GSK shares fell 3% after a phase III trial failure for its chronic cough drug camlipixant erased £2.36 billion in market value, more than the cost of acquiring BELLUS.